Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
EGFR-mutated lung cancer
Pharma
FDA approves J&J's new challenge to Tagrisso
Subcutaneous Rybrevant will be a better tool for J&J in its uphill fight against AstraZeneca’s Tagrisso in EGFR-mutated lung cancer.
Angus Liu
Dec 18, 2025 10:40am
Akeso details ivonescimab's 1st overall survival win
Nov 7, 2025 11:30am
Merck grows more ambitious about 'workhorse' TROP2 ADC
Oct 20, 2025 4:00pm
Summit's global PD-1xVEGF data show new promising OS trend
Sep 7, 2025 3:30am
AstraZeneca bolsters Tagrisso's case amid J&J rivalry
Sep 7, 2025 2:15am
Akeso, Summit's PD-1xVEGF drug meets OS goal for the first time
Aug 26, 2025 11:36am
